COmBining memantine And cholinesterase inhibitors in Lewy body dementia treatment Trial (COBALT)

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1191765

Funding Status
Status not available

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Many people who have been diagnosed with dementia with Lewy bodies or Parkinson’s disease dementia will be prescribed drugs known as acetylcholinesterase inhibitors (e.g. donepezil, rivastigmine, galantamine) to help with their symptoms. This research trial, known as COBALT, is designed to find out whether there is any benefit from taking the drug memantine as well. Australian and UK researchers are collaborating on this trial which will recruit eligible participants from both countries.

Funded Activity Details

Start Date: 01-01-2020

End Date: End date not available

Funding Scheme: International Collaborations

Funding Amount: $1,218,120.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

clinical trial | geriatrics | parkinson disease | dementia

Related Links